Agenus (NASDAQ:AGEN) Shares Pass Above 200 Day Moving Average of $2.82

Shares of Agenus Inc (NASDAQ:AGEN) crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $2.82 and traded as high as $2.83. Agenus shares last traded at $2.81, with a volume of 15,275 shares.

A number of equities analysts have recently issued reports on AGEN shares. BidaskClub lowered shares of Agenus from a “sell” rating to a “strong sell” rating in a research report on Friday, July 26th. B. Riley started coverage on shares of Agenus in a research report on Monday, April 22nd. They set a “buy” rating and a $5.00 target price on the stock.

The firm has a market capitalization of $374.86 million, a P/E ratio of -1.97 and a beta of 1.86. The stock’s 50 day moving average is $2.58 and its two-hundred day moving average is $2.82.



Agenus (NASDAQ:AGEN) last posted its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.38) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.33) by ($0.05). The company had revenue of $15.72 million for the quarter, compared to analyst estimates of $5.37 million. Equities research analysts anticipate that Agenus Inc will post -0.99 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Rhumbline Advisers raised its stake in shares of Agenus by 5.4% during the first quarter. Rhumbline Advisers now owns 118,079 shares of the biotechnology company’s stock worth $351,000 after buying an additional 6,064 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of Agenus by 28.3% during the second quarter. JPMorgan Chase & Co. now owns 28,741 shares of the biotechnology company’s stock worth $85,000 after buying an additional 6,332 shares during the last quarter. Legal & General Group Plc raised its stake in shares of Agenus by 47.7% during the fourth quarter. Legal & General Group Plc now owns 21,674 shares of the biotechnology company’s stock worth $52,000 after buying an additional 7,002 shares during the last quarter. Bank of Montreal Can raised its stake in shares of Agenus by 443.8% during the second quarter. Bank of Montreal Can now owns 10,675 shares of the biotechnology company’s stock worth $32,000 after buying an additional 8,712 shares during the last quarter. Finally, Northern Trust Corp raised its stake in shares of Agenus by 0.9% during the second quarter. Northern Trust Corp now owns 1,167,016 shares of the biotechnology company’s stock worth $3,501,000 after buying an additional 10,663 shares during the last quarter. 33.39% of the stock is owned by institutional investors and hedge funds.

Agenus Company Profile (NASDAQ:AGEN)

Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.

Featured Story: What is Call Option Volume?

Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.